Kirin (OTCMKTS:KNBWY) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Kirin Holdings Co. (OTCMKTS:KNBWY) saw unusually-high trading volume on Wednesday . 45,402 shares were traded during mid-day trading, an increase of 57% from the previous session’s volume of 29,009 shares.The stock last traded at $18.23 and had previously closed at $18.5350.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Kirin from a “hold” rating to a “strong sell” rating in a research note on Monday, August 31st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Kirin has an average rating of “Sell”.

Kirin Stock Down 1.6%

The business’s 50-day moving average is $18.52 and its two-hundred day moving average is $17.25. The firm has a market capitalization of $14.59 billion, a price-to-earnings ratio of 11.47 and a beta of -0.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.01 and a current ratio of 1.44.

Kirin (OTCMKTS:KNBWY) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.16. Kirin had a net margin of 7.79% and a return on equity of 12.29%. The firm had revenue of $4.08 billion during the quarter, compared to analysts’ expectations of $3.87 billion. On average, equities analysts anticipate that Kirin Holdings Co. will post 1.34 earnings per share for the current year.

Kirin Company Profile

Kirin Holdings Company, Limited is a Japan-based company with businesses spanning alcoholic and nonalcoholic beverages, pharmaceuticals and health science. Its beverage operations include beer, wine, spirits, soft drinks, bottled water and other consumer products marketed under brands such as Kirin, Ichiban Shibori and Afternoon Tea.

The company’s pharmaceutical business is conducted primarily through Kyowa Kirin, which researches, develops and commercializes prescription medicines, including treatments in areas such as oncology, immunology and nephrology.